Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBIT Margin (2016 - 2025)

China Pharma Holdings filings provide 16 years of EBIT Margin readings, the most recent being 97.9% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 758.0% to 97.9% in Q4 2025 year-over-year; TTM through Dec 2025 was 78.16%, a 2317.0% increase, with the full-year FY2025 number at 78.16%, up 2317.0% from a year prior.
  • EBIT Margin hit 97.9% in Q4 2025 for China Pharma Holdings, down from 83.06% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 48.14% in Q4 2022 to a low of 150.44% in Q2 2024.
  • Median EBIT Margin over the past 5 years was 44.95% (2022), compared with a mean of 47.06%.
  • Biggest five-year swings in EBIT Margin: plummeted -14258bps in 2024 and later soared 8687bps in 2025.
  • China Pharma Holdings' EBIT Margin stood at 47.14% in 2021, then rose by 2bps to 48.14% in 2022, then decreased by -23bps to 37.1% in 2023, then crashed by -384bps to 105.47% in 2024, then rose by 7bps to 97.9% in 2025.
  • The last three reported values for EBIT Margin were 97.9% (Q4 2025), 83.06% (Q3 2025), and 63.57% (Q2 2025) per Business Quant data.